Cytoreductive nephrectomy (CN) remains a mainstay in the treatment of metastatic renal cell carcinoma (mRCC). Prior literature has shown around 2/3rds of patients do not receive timely systemic therapy (ST) after CN, however there is limited understanding of how a delay affects progression and survival. Our aim was to identify whether a delay of the initiation of ST was associated with worse overall survival as well as to further characterize the reasons for a delay.
INTRODUCTION AND OBJECTIVES:
Cytoreductive nephrectomy (CN) remains a mainstay in the treatment of metastatic renal cell carcinoma (mRCC). Prior literature has shown around 2/3rds of patients do not receive timely systemic therapy (ST) after CN, however there is limited understanding of how a delay affects progression and survival. Our aim was to identify whether a delay of the initiation of ST was associated with worse overall survival as well as to further characterize the reasons for a delay.
METHODS: From an institutional database of 2,906 patients surgically treated for renal masses between 2005 and 2016, we identified 70 patients who underwent CN for mRCC and who were initiated on ST in the adjuvant setting. Cox regression analysis was used to evaluate whether delays in systemic therapy > 3 months and > 6 months were predictive of worse overall survival. RESULTS: Of the 70 patients, the majority had a favorable ECOG performance status (90% ECOG 0-1, 10% ECOG 2-3) while only 3 patients had brain metastasis at time of CN. Median age at diagnosis was 60 years. Our cohort had a 2-year overall survival of 60.8% from diagnosis and 49.4% after initiation of ST with a median follow-up of 27.1 months. Median time to ST after CN was 3 months (IQR 1.53-6.77). 94.2% of patients received targeted therapy while the remainder were treated with IL-2. Delays in initiating ST after CN were not associated with worse overall survival > 3 months after CN (HR ¼ 0.64, p¼ 0.387, 95% CI 0.24-1.75) and from 3 to <6 months (HR ¼ 0.5, p ¼ 0.208, 95% CI 0.17-1.47). Interestingly, delays in ST > 6 months were associated with improved survival (HR ¼ 0.19, p¼0.017, 95% CI 0.74-0.017). Of the patients who experienced unintended delays, 42.3% were awaiting a clinical trial, 30.8% experienced delayed ST due to patient preference or poor follow-up, and 19.2% had a complication from surgical therapy.
CONCLUSIONS: A delay in the initiation of ST in patients with mRCC after CN did not appear to be associated with worse overall survival. The improved survival in patients who initiated ST > 6 months and trend towards improved survival at > 3 months after CN is likely related to an immortal time bias. Ongoing randomized controlled trials may provide more evidence regarding the optimal timing of ST after CN and the clinical implications of a delay in ST. , with up to 20% of tumours exhibiting de novo resistance to TKIs. At present, there is no method of predicting response to systemic targeted therapy. We present a descriptive study of a prospective cohort of mRCC patients & the correlation of clinical outcomes to the responses predicted by patient-derived xenograft (PDX) models using the ex-ovo avian embryo.
METHODS: We prospectively collected demographic, pathologic, & clinical data on 26 patients with mRCC undergoing cytoreductive nephrectomy. PDX models were tested in 5 patients. Six core biopsies were taken from each primary tumor. Cores were sectioned & engrafted directly onto embryonic day 9 chorioallantoic membranes (CAMs) of avian embryos & treated with topical sunitinib or a DMSO control. On day 6 post-engraftment, Doppler & contrast-enhanced ultrasound were performed to assess vascularity & perfusion of tumours grown on the CAM models. A composite vascularity & perfusion score was obtained and used to determine the presence or absence of a response to TKIs compared to the control. Tumours were considered TKI-sensitive if there was a response in 4 cores. Tumours with responses in 3 cores were considered TKI-resistant. Clinical progression on CT scan was based on RECIST criteria.
RESULTS: Results are summarized in Table 1 . All tumours demonstrated heterogeneous responses to TKIs in the PDX model. Using the criteria of 4 cores responding to TKI therapy, we would expect a good response in patient 3, who does not have evidence of clinical progression after 5 months of maintenance on sunitinib. Moreover, patient 3 had 3 cores engrafted from a metastatic deposit, which all responded well to sunitinib in the PDX model. Patients 1 & 2 continued to show signs of progression despite switching to alternative agents, and both have discontinued systemic therapy due to intolerable side effects or enrolment in another clinical trial respectively. Patients 4 & 5 have not started on systemic targeted therapy.
CONCLUSIONS: Further studies in a larger population are warranted to explore the potential of the PDX model to serve as a novel phenotypic biomarker in the prediction of targeted therapy tumor resistance in RCC.
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